Market Overview

UPDATE: JP Morgan Initiates Kythera Biopharmaceuticals at Overweight on Key Pipeline Asset

Related KYTH
Benzinga's Top Downgrades
Leerink Swann Downgrades Kythera Biopharmaceuticals To Market Perform
Allergan Is Buying Its Way To Growth (Investor's Business Daily)

JP Morgan initiated coverage on Kythera Biopharmaceuticals (NASDAQ: KYTH) with an Overweight rating and a $30 price target.

JP Morgan noted, "There are currently no approved non-surgical options for the reduction of submental (under-chin) fat and Kythera will target this market with a non-invasive injectable therapy. We see a meaningful opportunity for ATX-101 to initially target the estimated 2 million unique patients in the US who currently receive a toxin and/or dermal filler with a longer term opportunity to address the estimated 10 million individuals who would be physically and financially appropriate for the treatment. Our recent survey of 50 dermatologists and plastic surgeons confirmed a high level of interest in the product in both opportunities and also highlighted a number of off-label opportunities for ATX-101."

Kythera Biopharmaceuticals closed at $22.11 on Friday.

Latest Ratings for KYTH

Jun 2015Leerink SwannDowngradesOutperformMarket Perform
Jun 2015Leerink SwannDowngradesOutperformMarket Perform
Jun 2015Guggenheim SecuritiesInitiates Coverage onBuy

View More Analyst Ratings for KYTH
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (KYTH)

Around the Web, We're Loving...

Get Benzinga's Newsletters